Almost all patients with pain have mixed pain states, so working out effective therapies for their pain depends on the proportion of each type of pain they have: nociceptive/neuropathic/centralised pain #ACR19 FM MTP Prof Clauw @RheumNow

Bechterew’s disease is an eponym for AS. #ACR19 @RheumNow knowledge bowl!

Benjamin Franklin had PsO which may have predisposed him to gout. Hippocrates is credited with the first description of scleroderma!pearls from Knowledge Bowl preliminaries. #ACR19 @RheumNow

Dr Robert Terkeltaub gives a great presentation summarizing the mechanistic complexity of hyperuricemia and gout. A one slide summary shows us the many aspects of disease. #gout #uricacid #hyperuricemia #ACR2019 @RheumNow https://t.co/qnGV71OvD4

Looks like the numbers are in. Last year’s great debate with Dr Petri who argued to keep HCQ 6.5mg/kg/d in SLE lost out to what rheums do in clinical practice @rheumnow

@ACR19 @rheumnow #ACRBest Abstr#L01:Risk for hosp serious infx (SIE) in PsO/PsA from multi-databse cohort (n=123,383) w/TNFi/IL17i/IL12-23i/or apremilast 1. Highest risk w/Infliximb 2. Lowest risk w/Ixekizmb & ustekmb 3. Ustekmb had lowest risk even when compared to apremilast

Advice from Dan Clauw on using cannabinoids / CBD for pain. Chronic pain users should aim for 10:1 CBD:THC ratio #ACR19 @RheumNow MTP https://t.co/DHssq7jmlS

GUS (IL23p19) showed skin and joint improvement in PsA pts (naive and TNFi failures) at Q4W and Q8W. No new safety signals noted. https://t.co/m8lCISnKpK Plenary abs #807 #ACR19 @RheumNow https://t.co/LfdOBnalmw

• Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Act…

When using medications for fibromyalgia, which do you find most effective? #ACR19 @RheumNow

Mechanisms of pain. Rheums call it ‘centralised pain’ but it’s official name is ‘nociplastic’ pain 🙄 #ACR19 @RheumNow fibro MTP w Prof Clauw https://t.co/jdjyf6i63H

Long term results for GCA pts on TCZ: No new safety signals. Nearly 50% of those on TCZ QW maintained remission. Flares noted in PBO/ cessation TCZ and remission restored in majority once TCZ restarted. https://t.co/7KPDGfMGUC Plenary abs #808 #ACR19 @RheumNow https://t.co/v07Dg75Oyt

• Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Result…

Systemic JIA-associated lung disease...an emerging disease with dismal prognosis. Dr Bindstadt #ACR19 @rheumnow #Abstr  #ACRBest https://t.co/ISYXySNgyC

AA race strongest predictor of CVD risk in SLE with event risk peaking 1-2 years post dx. With this information, we need to better address this to protect our patients. https://t.co/feA4bcvuU2 Plenary abs #805 #ACR19 @RheumNow https://t.co/OdK5XvrpeJ

• Risk of Cardiovascular Disease in SLE Is Significant Early and Highlights Racia…

Patients self-rate opiates as most effective for #fibromyalgia Gabapentin least effective Abstract 0242 #ACR19 @RheumNow @samwhittle https://t.co/EoRTMJ6PI1

Following RITAZAREM, would you use rituximab maintenance for ANCA-associated vasculitis patients (cost aside)? @RheumNow